Seattle Genetics Earns Relative Strength Rating Upgrade – Investor's Business Daily

This post was originally published on this site

https://lh5.googleusercontent.com/proxy/gA6gfZFrToQEhJP6sW0B91G0HQ96vAlcgKazQPUxEJQQ8mholWs9shtunbgoCZ0G02u29JmQdrr-gTBKoe4g3d_FlpJ8xqEo34AfGLtZmNIo=-w150-h150-c

Seattle Genetics (SGEN) had its Relative Strength (RS) Rating upgraded from 88 to 92 Monday.

X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock’s price action over the trailing 52 weeks matches up against other publicly traded companies.

Decades of market research shows that the best stocks often have an RS Rating of at least 80 in the early stages of their moves.


Looking For The Best Stocks To Buy And Watch? Start Here


Seattle Genetics broke out earlier, but has fallen back below the prior 78.16 entry from a cup with handle. If a stock you’re tracking clears a buy point then declines 7% or more below the original entry price, it’s considered a failed base. Wait for the stock to set up and breakout from a new base and buy point. Also understand that the latest pattern is a later-stage base, and those involve more risk.

While EPS growth dropped in the company’s most recent quarterly report from 0% to -119%, the top line rose 35%, up from 25% in the prior report. Look for the next report on or around Apr. 26.

The company holds the No. 132 rank among its peers in the Medical-Biomed/Biotech industry group. Alexion Pharmaceuticals (ALXN), Biospecifics Technologies (BSTC) and (OSIR) are among the top 5 highly rated stocks within the group.

YOU MAY ALSO LIKE:

Biotech And Pharmaceutical Industry And Stock News

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

This post was originally published on *this site*